Kamada Ltd. (KMDA), a global biopharmaceutical company specializing in plasma-derived therapies, continues to demonstrate steady operational strength and clinical progress. With recent approvals, solid financials, and advancing programs, the company continues to build momentum. Notably, its pivotal Phase 3 InnovAATe trial for inhaled Alpha-1 Antitrypsin (AAT) therapy is undergoing an interim futility analysis this quarter, highlighting Kamada's dual focus on plasma capacity expansion and late-stage innovation.
Company Overview
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.